Gómez-Sifontes, A. , Diaz-Tablero, J. and Rodriguez, Y. (2025) Anti-C1q Antibodies as Markers of Renal Involvement in Patients with Systemic Lupus Erythematosus, Bolivar City, Venezuela. Open Access ...

A biotech company developing precision therapeutics that selectively eliminate pathogenic antibodies driving autoimmune and ...

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...

US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing ...

Merida has developed a novel platform to precisely target the pathogenic antibodies that underpin a wide array of autoimmune and allergic diseases. The company is developing antib ...

The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment ...

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing ...

Kidney disease is often called a “silent killer” because it progresses unnoticed until it reaches an advanced stage. Millions ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...

competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other ...